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What do patients with chronic obstructive pulmonary disease die from?
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Chronic obstructive pulmonary disease (COPD)
is a condition characterised by a duration of several
decades. The main cause of mortality due to COPD in
developed countries is smoking and the main feature
of this disorder is a progressive decrease in ventilato-
ry reserve of the lungs of the obstructive type.
Over the decades-long course of the disease
forced expiratory volume in one second (FEV1) de-
creases by an average of 40 ml per year. When FEV1
drops below 50% predicted the patient may deve-
lop respiratory failure — a condition in which the
lungs are unable to supply sufficient amounts of
oxygen to the tissues and to remove excess carbon
dioxide from the tissues. Respiratory failure is a
complication of COPD and is the main cause of
death, which usually occurs during an acute exa-
cerbation of the disease [1].
Chronic hypoxia caused by respiratory failure is
the underlying cause of another complication of
COPD: hypoxic pulmonary hypertension, also refer-
red to as cor pulmonale. According to the data collec-
ted by the Epidemiology Department of the Institute
of Tuberculosis and Lung Diseases in Warsaw, Poland
[2], cor pulmonale was the cause of death in 10,524
patients in Poland in 1980. The frequency of this cau-
se of death is rapidly decreasing. In 2009, a total of
706 patients died from cor pulmonale in Poland.
If COPD patients had no co-morbidities, they
would most commonly die from the above compli-
cations. This, however, is not the case. COPD is
very prevalent. In some countries, it is the fourth
most common cause of death. The two main cau-
ses of mortality in developed countries, namely
cardiovascular disease and cancer, are commonly
seen in COPD patients for the very reason of their
high prevalence. Myocardial infarction and lung
cancer have been shown to be several times more
prevalent in COPD patients than in smokers with
normal lung function [3].
Interesting data on the causes of death in pa-
tients with COPD are provided in this issue of “Pneu-
monologia i Alergologia Polska”, in the paper by
Rubinsztajn and Chazan [4], in which the causes of
death in COPD patients hospitalised at a university
hospital pulmonary department were analysed.
Medical records of 266 consecutive COPD pa-
tients who were admitted to the department and died
during hospitalisation were analysed. The mean age
was 73 ± 8 years. The most common cause of death
(30% of the patients) was acute exacerbation of
COPD, followed by pneumonia (25%), followed by
lung cancer (19%). The fourth and fifth most com-
mon causes of death were ischaemic heart disease
(7%) and heart failure (5%), respectively.
The results of the study by Rubinsztajn and
Chazan [4] confirm that even in the advanced sta-
ge of COPD one fourth of the patients die from heart
disease and lung cancer. Of note is the fact that the
youngest were patients dying from lung cancer,
while the oldest were those dying from pneumo-
nia. A serious general condition on admission and
its further deterioration were the reasons why the
authors did not have spirometry results, which
would have allowed them to make an attempt at
relating the cause of death to the degree of ventila-
tory dysfunction of the lungs.
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ath in the United States [4]. A success of Polish
pneumonologists would be to reduce COPD-rela-
ted mortality. Unfortunately the COPD-related
mortality rate in 2009 was the highest in history
(20.5 per 100,000) [12]. Below I discuss the sugge-
sted courses of action which will most certainly
reduce mortality attributable to COPD in Poland.
An increasing body of evidence has accumu-
lated over the past 30 years to demonstrate that
complete cessation of smoking reduces COPD-re-
lated mortality [5]. Home oxygen therapy [13] and
non-invasive ventilation during hypercapnic respi-
ratory failure with uncompensated respiratory aci-
dosis [14] have also been shown to prolong survi-
val in patients with COPD. Both treatments are
insufficiently used in Poland [15–17].
Active diagnosis of COPD should be intensi-
fied. Unfortunately, despite the ten years of efforts
to disseminate spirometry testing in groups of pa-
tients at high risk of COPD in Poland [18] a re-
cent study to assess the prevalence of COPD in
general practice has shown that only 24% of abo-
ut 1000 subjects investigated (55% of whom were
smokers and 90% of whom were over 40 years of
age) had previously undergone spirometry [19].
At the same time, the quality of spirometries per-
formed at GP surgeries needs improving [20]. Pa-
tients with COPD are predominated by those with
primary-level education and low income. Such
patients seek medical active at a very late stage
[21]. Active diagnosis of the disease could impro-
ve the situation.
Spirometry combined with permanent smo-
king cessation counselling leading to a definitive
cessation of smoking is the best way to stop the
progression of COPD and to prevent other smoking-
related conditions. Two long-term and very large
studies investigating the effects of smoking cessa-
tion on annual reduction of FEV1 have shown that
patients with COPD who continue to smoke lose
twice as much of their FEV1 than those who mana-
ged to quit smoking. Over a period of 11 years,
patients with mild to moderate COPD who conti-
nued to smoke lost an annual of 60 ml of FEV1,
while those who permanently quitted smoking lost
annually 26 ml [22]. Another study of patients with
moderate to severe disease who were followed up
for 4 years has shown that patients who were not
smoking during the study lost annually of 23 ml
of their FEV1, while those who were smoking lost
51 ml of their FEV1 per year. This means that smo-
king cessation stops the progression of the disease
at any stage, even at the stage of severe COPD [23].
Polish pneumonologists should therefore force the
National Health Fund to adopt new rules for the
In the largest and longest prospective study of
patients with mild to moderate COPD, a total of 5887
subjects aged 35 to 60 years were followed up for 14.5
years. Of the 731 deaths during this period nearly a
half (55%) was caused by heart disease or cancer [5].
Patients with severe respiratory failure requiring
home oxygen therapy are at the other end of the seve-
rity spectrum. In a large multicentre European analy-
sis of 215 patients with COPD receiving home oxygen
therapy [6], 72% of the subjects died from exacerba-
tion of respiratory failure or cor pulmonale. Myocar-
dial infarction or lung cancer were the cause of death
in 13% of the patients. Similar causes of death were
identified by Rubinsztajn and Chazan [4] in the sub-
group of patients receiving home oxygen therapy.
The relationships between age and the cause
of death and between the severity of the disease
and the cause of death presented above could be
one of the explanations of the widespread finding
in epidemiological studies, namely that patients
with mild to moderate disease account for 80% of
all COPD patients, while only 20% progress to se-
vere and very severe disease [7]. A large propor-
tion of patients with mild to moderate COPD die
from co-morbidities, mainly heart disease and can-
cer. I have intentionally used the word “co-morbi-
dities” in order to keep a certain reserve regarding
the opinion according to which COPD is a syste-
mic inflammatory disease that affects the develop-
ment of many disorders seen in COPD patients [8].
One of the findings confirming the inflamma-
tory hypothesis is the correlation between the le-
vels of markers of systemic inflammation, such as
C-reactive protein (CRP), interleukin-6 (IL-6) and
tumour necrosis factor-alfa (TNF-a), in patients
with COPD and the severity of the features of lung
distension, an indirect sign suggestive of emphy-
sema [9]. The presence of similar correlations does
not mean that they are clinically relevant and they
may be purely accidental.
If COPD was indeed an inflammatory disorder,
one could expect that anti-inflammatory drugs (an-
tibiotics, steroids) would affect its natural history and
disease-related mortality. So far no such relationship
has been demonstrated [10]. The discussion about
the inflammatory hypothesis in COPD is not only
academic in nature. Its practical result is the use of
anti-inflammatory drugs in each stage of COPD [11].
How to reduce mortality related to chronic ob-
structive pulmonary disease in Poland?
In their paper, Rubinsztajn and Chazan point
to the fact that within the next 10 years COPD will
have become the third most common cause of de-
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operation of smoking cessation clinics, both in
terms of the type of services provided and the pri-
cing of the procedures.
Non-invasive ventilatory support, i.e. the use
of a ventilator connected with the patient through
a mask, is a survival-prolonging treatment in COPD
patients. The method, improved and disseminated
by pneumonologists from the very beginning, has
considerably developed in Europe in the past 30
years. Used in the management of exacerbations of
hypercapnic respiratory failure with uncompensa-
ted respiratory acidosis, the method reduces mor-
tality by 50% compared to traditional treatment
(oxygen, antibiotics, bronchodilators and systemic
steroids) [14]. Compared to Western European co-
untries, non-invasive ventilatory support is very
rarely used in Poland [16], most commonly at aca-
demic facilities. Reduced mortality of COPD pa-
tients during acute exacerbations may be expected
after the accessibility to non-invasive ventilatory
support is increased during exacerbations of the
disease at hospitals, followed by continuation of this
form of treatment in some of the patients at home
[17]. At each pneumonology ward and department
in Poland it is necessary to create an intensive pul-
monary care unit with three monitored beds where
non-invasive ventilatory support can be provided.
This year marks the 25th anniversary of im-
plementation of home oxygen therapy in Poland.
Over these 25 years the rate of patients on home
oxygen therapy has reached 21 per 100,000 inha-
bitants. It is estimated that when the need for this
form of therapy is met this number should incre-
ase to 50 per 100,000. Although home oxygen the-
rapy is the simplest and the most accessible me-
thod of treatment, it is not fully taken advantage
of by Polish pneumonologists. Home oxygen the-
rapy prolongs survival, improves the quality of life,
reduces the number of acute exacerbations of
COPD and deceases hospitalisation rate. Who else,
if not Polish pneumonologists, should make every
effort to render this reimbursed method of treat-
ment fully utilised?
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